Influence of Increased C-Myc Expression on the Growth Characteristics of Human Melanoma
Overview
Affiliations
Overexpression of the proto-oncogene c-myc has been associated with neoplastic transformation in a variety of tumors. For human melanoma high c-myc expression has been found in the vertical growth phase and higher positivity reported in metastases than primary tumors. The principle aim of this study was to determine, whether c-Myc expression influences the metastatic behavior of human melanoma in the absence of lymphocyte-mediated immune phenomena. The growth characteristics and tumor biology of two c-myc transfectants of the human melanoma cell line IGR39D, expressing c-Myc 1.7 and three times over baseline and the respective vector control were analyzed both in vitro and in a severe combined immunodeficient mouse model in vivo. Both c-myc transfectants showed increased growth rates, anchorage independent growth and directed cell movement in culture. Subcutaneously implanted IGR39D melanomas highly overexpressing c-Myc spontaneously formed macroscopic metastases (lymph nodes and lung) in severe combined immunodeficient mice in all cases (n = 7 per group), whereas less prominent c-Myc overexpression caused the development of only lung micrometastases. During the time period leading to terminal disease in animals injected with c-myc transfected human melanoma cells, melanoma development was not seen in vector controls. These findings suggest that constitutive high c-Myc expression in human melanoma results in a more aggressive growth behavior both in vitro and in vivo and favors metastasis in severe combined immunodeficient mice by factors unrelated to immune phenomena such as class I human leukocyte antigen downregulation known to be associated with c-Myc expression.
Sandhya S, Talukdar J, Gogoi G, Dey K, Das B, Baishya D Heliyon. 2024; 10(8):e29385.
PMID: 38665592 PMC: 11043960. DOI: 10.1016/j.heliyon.2024.e29385.
Identification of MYC intron 2 regions that modulate expression.
Tompkins V, Xue Z, Peterson J, Rouse W, OLeary C, Moss W PLoS One. 2024; 19(1):e0296889.
PMID: 38236931 PMC: 10795982. DOI: 10.1371/journal.pone.0296889.
Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma.
Zacarias-Fluck M, Masso-Valles D, Giuntini F, Gonzalez-Larreategui I, Kaur J, Casacuberta-Serra S Genes Dev. 2023; 37(7-8):303-320.
PMID: 37024284 PMC: 10153459. DOI: 10.1101/gad.350078.122.
Wilcock D, Badrock A, Wong C, Owen R, Guerin M, Southam A Cell Rep. 2022; 39(12):110995.
PMID: 35732120 PMC: 9638004. DOI: 10.1016/j.celrep.2022.110995.
Dickerhoff J, Dai J, Yang D Nucleic Acids Res. 2021; 49(10):5905-5915.
PMID: 33978746 PMC: 8191789. DOI: 10.1093/nar/gkab330.